Intellia Therapeutics is a biopharmaceutical company developing potentially curative in vivo genome editing therapies using CRISPR, oligonucleotides, and lipid nanoparticle technologies to treat the root causes of severe genetic diseases. The company's lead candidates are designed to address hereditary angioedema and transthyretin amyloidosis through one-time intravenous infusions that provide durable reductions in disease-causing proteins, targeting large patient populations that currently require lifelong symptomatic therapy. Intellia generates value through advancing its pipeline of novel therapeutics, building commercial infrastructure, and leveraging strategic partnerships including a co-development agreement with Regeneron for one of its lead programs, while protecting its technology through a broad patent portfolio of CRISPR and delivery innovations.